Onxeo extends US patent portfolio
The Danish-French biotech company Onxeo has expanded its patent portfolio and obtained another patent in the US. The patent is related to the company’s main product, the primary liver cancer drug Livatag.
BY ELIZABETH MØNSTED JOHANSEN
Recently, the Danish-French biotech company Onxeo has been working on expanding its patent portfolio on the important US market. The goal has been to obtain a Notice of Allowance for the primary liver cancer drug Livatag. And now, the company announced that the US Patent and Trademark Office have granted Onxeo one more patent.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Onxeo raises millions for pipeline activities
For abonnenter
Onxeo CEO: Real life does not take place in the clinic
For abonnenter
Onxeo wins important new patent
For abonnenter
